Hikma Pharmaceuticals Plc Hikma announces injectable licensing agreement
November 27 2018 - 3:00AM
RNS Non-Regulatory
TIDMHIK
Hikma Pharmaceuticals Plc
27 November 2018
London, 27 November 2018 - Hikma Pharmaceuticals PLC (Hikma,
Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1
Moody's / BB+ S&P, both stable) today announced a five-year
licensing and supply agreement with Hansoh Pharmaceutical Group
Co., Ltd. (Hansoh), one of the few research and development-driven
Chinese pharmaceutical companies with leading franchises in
multiple large and fast-growing therapeutic areas.
The agreement provides Hikma with exclusive rights to market a
suite of Hansoh's injectable oncology medicines within the US for
the next five years. Hansoh expects to file these products for
approval with the FDA within the next 12 months.
"Our partnership with Hansoh will expand Hikma's growing US
portfolio of vital injectable oncology medicines and strengthens
our ability to serve the growing needs of US hospitals, physicians
and patients," said Daniel Motto, Hikma's Executive Vice President
of Commercial and Business Development. "We look forward to
building relationships with Hansoh and other potential partners
whose pharmaceutical products can benefit from our strong
commercial relationships and our well-established sales and
marketing infrastructure."
"Today one out of every six generic injectable products used in
US hospitals is a Hikma product, and we plan to continue adding
specialised products like these to our growing portfolio of
essential medicines," said Riad Mechlaoui, Hikma's President of
Injectables.
-- ENDS -
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal +44 (0)20 7399 2760/ +44 7776
EVP, Strategic Planning and Global 477050
Affairs uk-investors@hikma.com
Steven Weiss +1 732 720 2830/ +1 732 788 8279
Senior Director, Communications sweiss@hikma.com
and Public Affairs
FTI Consulting
Ben Atwell/Brett Pollard +44 (0)20 3727 1000
About Hikma
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
40 years, we've been creating high-quality medicines and making
them accessible to the people who need them. We're a global company
with a local presence across the United States (US), the Middle
East and North Africa (MENA) and Europe, and we use our unique
insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers, and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,500 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner in
the MENA region, and through our venture capital arm, are helping
bring innovative health technologies to people around the world.
For more information, please visit www.hikma.com.
About Hansoh Pharmaceuticals, Inc.
Hansoh Pharma is one of the few research and development-driven
Chinese pharmaceutical companies with established leadership
positions in some of China's largest and fastest-growing
therapeutic areas including central nervous system, oncology,
anti-infectives and diabetes. With world-class production
facilities and manufacturing quality-management systems that comply
with the cGMP requirements of China, the US and Japan, Hansoh
Pharma is able to export high-quality injectable pharmaceuticals to
developed markets to address significant clinical needs.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRABLBDBBXDBGIL
(END) Dow Jones Newswires
November 27, 2018 04:00 ET (09:00 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Apr 2024 to May 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From May 2023 to May 2024